Aquestive Therapeutics is expected to report Q3 2026 revenue of $15.42 million and a consensus EPS loss of $0.10, with the stock trading at $5.24 against a $12.00 average analyst target.
Investors are primarily focused on the regulatory status and potential NDA filing timeline for Anaphylm, the company’s needle-free epinephrine sublingual film. Recent performance has been supported by steady growth in Sympazan sales, although increased R&D spending for the Anaphylm clinical program continues to impact the bottom line.
Management's commentary on the cash runway and the commercialization strategy for its pipeline candidates remains a critical focal point for the market.